{"id":"https://openalex.org/W4391095461","doi":"https://doi.org/10.1200/jco.2024.42.3_suppl.tps227","title":"Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.","display_name":"Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.","publication_year":2024,"publication_date":"2024-01-20","ids":{"openalex":"https://openalex.org/W4391095461","doi":"https://doi.org/10.1200/jco.2024.42.3_suppl.tps227"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2024.42.3_suppl.tps227","doi":"https://doi.org/10.1200/jco.2024.42.3_suppl.tps227","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1200/jco.2024.42.3_suppl.tps227","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034115525","display_name":"Aparna R. Parikh","orcid":"https://orcid.org/0000-0002-5245-7841","observed_orcids":["https://orcid.org/0000-0002-5245-7841"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aparna Raj Parikh","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044508050","display_name":"Vedran Radoj\u010di\u0107","orcid":"https://orcid.org/0000-0002-9699-1157","observed_orcids":["https://orcid.org/0000-0002-9699-1157"]},"institutions":[{"id":"https://openalex.org/I4405271706","display_name":"Syndax Pharmaceuticals (United States)","ror":"https://ror.org/02w9kv048","country_code":"US","type":"company","lineage":["https://openalex.org/I4405271706"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vedran Radojcic","raw_affiliation_strings":["Syndax Pharmaceuticals, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Syndax Pharmaceuticals, Waltham, MA","institution_ids":["https://openalex.org/I4405271706"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108695315","display_name":"Myles Steven Clancy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405271706","display_name":"Syndax Pharmaceuticals (United States)","ror":"https://ror.org/02w9kv048","country_code":"US","type":"company","lineage":["https://openalex.org/I4405271706"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Myles Clancy","raw_affiliation_strings":["Syndax Pharmaceuticals, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Syndax Pharmaceuticals, Waltham, MA","institution_ids":["https://openalex.org/I4405271706"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002138223","display_name":"Susan Brouwer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405271706","display_name":"Syndax Pharmaceuticals (United States)","ror":"https://ror.org/02w9kv048","country_code":"US","type":"company","lineage":["https://openalex.org/I4405271706"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan Brouwer","raw_affiliation_strings":["Syndax Pharmaceuticals, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Syndax Pharmaceuticals, Waltham, MA","institution_ids":["https://openalex.org/I4405271706"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024381625","display_name":"Shaliny Kushwaha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405271706","display_name":"Syndax Pharmaceuticals (United States)","ror":"https://ror.org/02w9kv048","country_code":"US","type":"company","lineage":["https://openalex.org/I4405271706"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shaliny Kushwaha","raw_affiliation_strings":["Syndax Pharmaceuticals, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Syndax Pharmaceuticals, Waltham, MA","institution_ids":["https://openalex.org/I4405271706"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052937521","display_name":"Yifan Huang","orcid":"https://orcid.org/0000-0003-1060-3668","observed_orcids":["https://orcid.org/0000-0003-1060-3668"]},"institutions":[{"id":"https://openalex.org/I4405271706","display_name":"Syndax Pharmaceuticals (United States)","ror":"https://ror.org/02w9kv048","country_code":"US","type":"company","lineage":["https://openalex.org/I4405271706"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yifan Huang","raw_affiliation_strings":["Syndax Pharmaceuticals, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Syndax Pharmaceuticals, Waltham, MA","institution_ids":["https://openalex.org/I4405271706"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111512954","display_name":"Nashat Y. Gabrail","orcid":"https://orcid.org/0009-0007-3885-3622","observed_orcids":["https://orcid.org/0009-0007-3885-3622"]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nashat Gabrail","raw_affiliation_strings":["Gabrail Cancer Center, Canton, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gabrail Cancer Center, Canton, OH","institution_ids":["https://openalex.org/I4210100169"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"42","issue":"3_suppl","first_page":"TPS227","last_page":"TPS227"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9599999785423279,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9599999785423279,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10929","display_name":"Wnt/\u03b2-catenin signaling in development and cancer","score":0.016100000590085983,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.0066999997943639755,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/revumenib","display_name":"revumenib","score":1.0},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.8460000157356262},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.7570000290870667},{"id":"https://openalex.org/keywords/epigenetic-therapy","display_name":"epigenetic therapy","score":0.6570000052452087},{"id":"https://openalex.org/keywords/wnt-beta-catenin-signaling","display_name":"Wnt/\u03b2-catenin signaling","score":0.847000002861023},{"id":"https://openalex.org/keywords/kmt2a","display_name":"KMT2A","score":0.6240000128746033},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5230000019073486},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8059999942779541},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.7089999914169312},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.7409999966621399},{"id":"https://openalex.org/keywords/estrogen-receptor-positive-breast-cancer","display_name":"estrogen receptor-positive breast cancer","score":0.859000027179718},{"id":"https://openalex.org/keywords/gastrointestinal-stromal-tumor","display_name":"gastrointestinal stromal tumor","score":0.8939999938011169},{"id":"https://openalex.org/keywords/ewing-sarcoma","display_name":"Ewing sarcoma","score":0.996999979019165}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8497520685195923},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.6523324847221375},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5607354044914246},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.5512189269065857},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.5131047964096069},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5066412091255188},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5008730888366699},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4905170798301697},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.45275378227233887},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.450950562953949},{"id":"https://openalex.org/C2777088508","wikidata":"https://www.wikidata.org/wiki/Q944777","display_name":"Endometrial cancer","level":3,"score":0.43262699246406555},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.21624112129211426},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.1875188648700714}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2024.42.3_suppl.tps227","doi":"https://doi.org/10.1200/jco.2024.42.3_suppl.tps227","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1200/jco.2024.42.3_suppl.tps227","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.7900000214576721,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320317987","display_name":"Syndax Pharmaceuticals","ror":"https://ror.org/02w9kv048"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7122887419","https://openalex.org/W2999034871","https://openalex.org/W2275428290","https://openalex.org/W2406975007","https://openalex.org/W4389060129","https://openalex.org/W4365512298","https://openalex.org/W2908906089","https://openalex.org/W4205284999","https://openalex.org/W2977398957","https://openalex.org/W4238735537"],"abstract_inverted_index":{"TPS227":[0],"Background:":[1],"Aberrant":[2],"transcription":[3],"in":[4,16,34,56,60,79,106,116,143,163,243,286,306,316,331,337,424],"cancer":[5,81],"can":[6],"be":[7,193,300,314,324,362,383,399],"reversed":[8],"by":[9,20,30,48,270,411],"targeting":[10],"critical":[11],"epigenetic":[12],"regulators.":[13],"For":[14],"example,":[15],"acute":[17],"leukemias":[18],"driven":[19],"increased":[21],"HOX":[22],"gene":[23],"expression,":[24],"inhibition":[25,68],"of":[26,52,69,101,131,160,179,241,268,277,372,391,393,416,427],"the":[27,49,53,70,98,103,132,212,230,265,295],"menin-KMT2A":[28,71,104,133],"interaction":[29,72,105],"revumenib":[31,115,142,242,269,296,387],"induced":[32],"remission":[33],"patients":[35,117,164,244,312,378,421],"with":[36,75,118,148,165,190,245,379,404],"heavily":[37],"pretreated":[38],"disease":[39,199,351],"(Issa":[40],"et":[41],"al":[42],"2023).":[43],"In":[44,375],"solid":[45,107,122,167,187,249],"tumors":[46,168,250],"promoted":[47],"aberrant":[50],"activation":[51],"Wnt/\u03b2-catenin":[54],"pathway,":[55],"vitro":[57],"data":[58],"and":[59,93,120,162,205,236,247,251,283,326,357,368,409],"vivo":[61],"studies":[62],"have":[63,155,170,198,215],"shown":[64],"that":[65,200],"small":[66],"molecule":[67],"restricts":[73],"growth,":[74],"potential":[76,343],"therapeutic":[77,99],"benefit":[78],"colorectal":[80],"(CRC),":[82],"castration-resistant":[83],"prostate":[84],"cancer,":[85,89],"estrogen":[86],"receptor\u2013positive":[87],"breast":[88],"gastrointestinal":[90],"stromal":[91],"tumors,":[92],"Ewing":[94],"sarcoma.":[95],"To":[96],"test":[97],"strategy":[100],"inhibiting":[102],"tumor":[108,333],"malignancies,":[109],"this":[110,428],"study":[111,139],"(NCT05731947)":[112],"will":[113,299,313,339,361,369,382,398],"evaluate":[114],"CRC":[119,153,184,191,246,287,338,381],"other":[121,166,186,248],"tumors.":[123,188],"Revumenib":[124],"is":[125,140,262],"an":[126],"oral,":[127],"potent,":[128],"selective":[129],"inhibitor":[130],"interaction.":[134],"Methods:":[135],"This":[136],"phase":[137,224,238,258,344,373,376,425],"1/2":[138],"evaluating":[141],"adults":[144],"aged":[145],"\u226518":[146],"years":[147],"locally":[149,408],"recurrent":[150],"or":[151,185,197,388],"metastatic":[152],"who":[154,169],"failed":[156,171],"\u22651":[157],"prior":[158],"line":[159],"therapy":[161],"available":[172],"standard":[173],"therapies.":[174,396],"Inclusion":[175],"criteria":[176],"include":[177],"diagnosis":[178],"microsatellite":[180],"stable/proficient":[181],"mismatch":[182],"repair":[183],"Patients":[189,397],"must":[192,214],"unable":[194],"to":[195,228,252,263,310,364,386],"receive":[196],"progressed":[201],"on":[202],"oxaliplatin,":[203],"irinotecan,":[204],"bevacizumab;":[206],"if":[207],"left-sided":[208],"RAS":[209],"wild-type":[210],"CRC,":[211],"patient":[213],"received":[216],"anti\u2013epidermal":[217],"growth":[218],"factor":[219],"receptor":[220],"therapy.":[221],"The":[222,257,350],"primary":[223,260],"1":[225,275,392],"objectives":[226],"are":[227],"determine":[229,370],"safety,":[231],"tolerability,":[232],"maximum":[233],"tolerated":[234],"dose,":[235],"recommended":[237],"2":[239,259,345,394],"dose":[240,279,298,318,346],"assess":[253,264,365],"its":[254],"antitumor":[255,266,366],"effects.":[256],"objective":[261],"effects":[267],"blinded":[271,412],"radiographic":[272,413],"review.":[273,414],"Phase":[274,335],"consists":[276],"all-comers\u2019":[278],"escalation":[280,321],"(phase":[281,288],"1a),":[282],"signal-seeking":[284],"expansion":[285],"1b).":[289],"Using":[290],"a":[291,317,342],"rolling":[292],"6":[293,311,355],"design,":[294],"starting":[297],"163":[301],"mg":[302],"3":[303],"times":[304],"daily":[305],"28-day":[307],"cycles.":[308],"Up":[309],"enrolled":[315,423],"cohort.":[319],"Dose":[320],"cohorts":[322],"may":[323],"expanded":[325],"used":[327,363],"for":[328,401],"signal":[329],"seeking":[330],"non-CRC":[332],"types.":[334],"1b":[336],"begin":[340],"when":[341],"has":[347],"been":[348],"identified.":[349],"control":[352],"rate":[353,360],"at":[354],"cycles":[356],"overall":[358],"response":[359,405],"activity":[367],"initiation":[371],"2.":[374],"2,":[377],"advanced":[380],"randomized":[384],"2:1":[385],"investigator's":[389],"choice":[390],"standard-of-care":[395],"followed":[400],"progression-free":[402],"survival,":[403],"assessments":[406],"evaluated":[407],"confirmed":[410],"As":[415],"September":[417],"5,":[418],"2023,":[419],"13":[420],"were":[422],"1a":[426],"study.":[429],"Clinical":[430],"trial":[431],"information:":[432],"NCT05731947":[433],".":[434]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2024-01-23T00:00:00"}